Get the Stockscreener App
23.70
0.64%
0.15
Pre-market:
25.98
2.28
+9.62%
Newamsterdam Pharma Company Nv stock is traded at $23.70, with a volume of 933.54K.
It is up +0.64% in the last 24 hours and down -7.06% over the past month.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
See More
Previous Close:
$23.55
Open:
$23.59
24h Volume:
933.54K
Relative Volume:
1.21
Market Cap:
$2.54B
Revenue:
$14.09M
Net Income/Loss:
$-176.94M
P/E Ratio:
-11.02
EPS:
-2.15
Net Cash Flow:
$-141.24M
1W Performance:
+0.13%
1M Performance:
-7.06%
6M Performance:
+25.40%
1Y Performance:
+21.54%
1-Day Range:
$23.17
$24.09
1-Week Range:
$22.53
$24.35
52-Week Range:
$15.19
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Name
Newamsterdam Pharma Company Nv
Sector
Industry
Phone
35 206 2971
Address
GOOIMEER 2-35, NARRDEN
Compare NAMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
23.70 | 2.54B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| May-15-24 | Initiated | TD Cowen | Buy |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-18-24 | Initiated | Guggenheim | Buy |
| Jan-16-24 | Initiated | Piper Sandler | Overweight |
| Oct-30-23 | Initiated | RBC Capital Mkts | Outperform |
View All
Newamsterdam Pharma Company Nv Stock (NAMS) Latest News
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $39.80 Consensus Price Target from Analysts - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 4.9%What's Next? - MarketBeat
NewAmsterdam Pharma’s (NAMS) “Buy” Rating Reiterated at HC Wainwright - Defense World
14 Best 52-Week High Stocks To Buy According to Analysts - Insider Monkey
NewAmsterdam Pharma Company N.V. (NAMS): Analysts Recommend This 52-Week High Stocks Now - Insider Monkey
NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Buy" Rating from HC Wainwright - MarketBeat
NewAmsterdam Pharma Company N.V. Issues Press Release and Corporate PresentationOn January 10, 2025, NewAmsterdam Pharma Company N.V. filed a Form 8-K with the Securities and Exchange Commission, highlighting significant achievements in 2 - Defense World
NewAmsterdam gears up for obicetrapib regulatory filings By Investing.com - Investing.com Australia
NewAmsterdam gears up for obicetrapib regulatory filings - Investing.com India
NewAmsterdam Pharma Achieves Key Milestones in 2024 - TipRanks
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities - The Manila Times
NewAmsterdam's Cholesterol Drug Achieves Major Breakthroughs: 33% LDL-C Drop in Phase 3 Trials - StockTitan
Geode Capital Management LLC Purchases 1,399 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma Grants Equity Awards to New Chief People Officer, Key Hires - StockTitan
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Barclays PLC - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Hits New 12-Month HighTime to Buy? - MarketBeat
State Street Corp Purchases 23,805 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
State Street Corp Buys 23,805 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Nap B.V. Forgrowth Sells 29,846 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
Brokers Offer Predictions for NAMS FY2024 Earnings - Defense World
FY2024 Earnings Estimate for NAMS Issued By HC Wainwright - MarketBeat
(NAMSW) On The My Stocks Page - Stock Traders Daily
Analyst Initiates Coverage of Co. With 'Once-in-a-Generation' Drug - Streetwise Reports
NAMSWNewAmsterdam Pharma Company N.V. Warrant Latest Stock News & Market Updates - StockTitan
NewAmsterdam Pharma's SWOT analysis: obicetrapib stock poised for cardiovascular market impact - Investing.com India
NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by HC Wainwright - Defense World
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Sells 33,438 Shares of Stock - MarketBeat
NewAmsterdam Pharma’s SWOT analysis: obicetrapib stock poised for cardiovascular market impact - Investing.com Nigeria
NewAmsterdam Pharma's SWOT analysis: obicetrapib stock poised for cardiovascular market impact By Investing.com - Investing.com South Africa
Newamsterdam Pharma's major shareholders sell shares worth $1.95 million - Investing.com
Obicetrapib’s data positions NewAmsterdam Pharma stock for growth, says H.C. Wainwright - Investing.com Nigeria
Where NewAmsterdam Pharma Stands With Analysts - Benzinga
NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Analysts at HC Wainwright - MarketBeat
Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $36.20 - Defense World
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Sells $1,274,163.20 in Stock - MarketBeat
Forbion capital fund iv sells NewAmsterdam pharma shares worth $2.3m - Investing.com
Where are the Opportunities in (NAMS) - Stock Traders Daily
Analysts Set NewAmsterdam Pharma (NASDAQ:NAMS) Price Target at $36.20 - MarketBeat
Newamsterdam Pharma sees $4.07 million in stock sales by Forbion funds - Investing.com India
Q1 Earnings Estimate for NAMS Issued By Leerink Partnrs - Defense World
(NAMSW) Technical Data - Stock Traders Daily
Nap B.V. Forgrowth Sells 100,728 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
What is Leerink Partnrs' Forecast for NAMS Q1 Earnings? - MarketBeat
What is Leerink Partnrs’ Estimate for NAMS Q4 Earnings? - Defense World
Q4 Earnings Estimate for NAMS Issued By Leerink Partnrs - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap DownWhat's Next? - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 4.7%Here's What Happened - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Nap B.V. Forgrowth Sells 166,011 Shares - MarketBeat
Newamsterdam Pharma Company Nv Stock (NAMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):